Summit Therapeutics Inc. Common Stock (SMMT) Financials
Key financial figures for Summit Therapeutics Inc. Common Stock (Q3 2026).
Summit reported a Q3 2026 GAAP net loss of $208.4 million ($0.26 per share) and $629.8 million of cash and short-term investments at September 30, before the $2.0 billion AstraZeneca investment received on October 5. Q3 2026 GAAP net loss was $208.4 million, or $(0.26) per basic and diluted share, versus $231.8 million, or $(0.31), in Q3 2025. The company reports no revenue. GAAP operating expenses were $214.6 million versus $234.2 million a year earlier; the release attributes the decrease to $83.1 million lower stock-based compensation tied to the Q2 2025 performance-option modification, partly offset by higher R&D. GAAP R&D was $169.1 million versus $131.1 million (up about 29%, calculated), driven by the expansion of clinical studies and ivonescimab development costs. Figures are for Q3 2026, as Summit Therapeutics Inc. reported them.
- Revenue
- $0
- Net Income
- -$208M
- EPS
- $-0.26
- Total Assets
- $693M
- Operating Cash Flow
- -$160M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q3 FY2026 | $0 | -$208M | -$0.26 | -$160M | |
| Q2 FY2026 | $0 | -$216M | -$0.28 | -$169M | |
| Q1 FY2026 | $0 | -$189M | -$0.24 | -$123M | |
| Q4 FY2025 | $0 | -$219M | -$0.29 | -$76M | |
| Q3 FY2025 | $0 | -$232M | -$0.31 | -$69M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $0 | -$1.1B | -$1.44 | -$324M | |
| FY2024 | $0 | -$221M | -$0.31 | -$142M | |
| FY2023 | $0 | -$615M | -$0.99 | -$77M |
Frequently asked questions
What was Summit Therapeutics Inc.'s revenue last quarter?
Summit Therapeutics Inc. reported revenue of $0.00 for Q3 FY2026.
Is Summit Therapeutics Inc. profitable?
Not in its most recent reported period. Summit Therapeutics Inc. reported a net loss of $208.4 million for Q3 FY2026.
How much free cash flow did Summit Therapeutics Inc. generate?
Summit Therapeutics Inc. generated free cash flow of -$160.2 million in Q3 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Summit Therapeutics Inc. Common Stock on SentiSense, with up to forty quarters and twenty fiscal years of history.